ATOMIC trial establishes new standard for adjuvant treatment in dMMR stage 3 colon cancer

Atezolizumab plus chemotherapy significantly reduced the risk of death or recurrence by 50% compared with chemotherapy alone for participants with stage 3 colon cancer characterised by deficient DNA mismatch repair (dMMR). Prof. Frank Sinicrope (Mayo Clinic, Rochester, MN, USA) presented this second interim analysis of the phase 3 ATOMIC trial (NCT02912559) [1]. The study enrolled 712 participants with resected stage 3 dMMR colon cancer. Eligible participants had no prior chemotherapy or radiotherapy and an ECOG performance status of 0–2. Following surgery, participants were randomised to receive either standard chemotherapy with mFOLFOX6 alone (oxaliplatin, leucovorin calcium, and fluorouracil) or the same regimen in combination with atezolizumab, followed by 6 months of atezolizumab monotherapy. The primary outcome was disease-free survival (DFS). The second interim analys...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 202531 July 2025